Patient preference: weekly injection vs potential monthly depot — need advice

Dr.ReproEndo said:

It helps to ask what evidence would change your mind before you look at any.

I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.

That is the short version; the long version is somebody else's post.

The figures, for anyone assembling their own picture. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

pete_manc_UK said:

I would rather people stopped quoting the 24% as if it were a licensed outcome.

Adding the part of the answer the thread has not reached. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

I would rather be corrected than agreed with, if it comes to it.

One thing that is still open after laura_annarbor’s answer:

Why adding glucagon agonism to an anti-obesity drug is not self-defeating, given that glucagon raises blood glucose?

Reporting back.

Rereading it with the dropout table open changed my view. I still think it is the most interesting molecule in the pipeline; I no longer think the 24% is the number that will end up on a label.